Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (33,978)	$ (7,830)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	9,746	424
Amortization of operating lease right-of-use asset	93
Depreciation	103	16
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	1,405	(37)
Other Assets	58
Accounts payable	198	366
Accrued expenses	(966)	2,050
Right-of-use liability	(66)
Net cash used in operating activities	(23,407)	(5,011)
Cash flows from investing activities:
Cash and restricted cash acquired in connection with the reverse merger with ArTara Therapeutics, Inc.	3,719
Purchase of property and equipment	(884)	(475)
Net cash provided by/(used in) investing activities	2,835	(475)
Cash flows from financing activities:
Proceeds from - ArTara Private Placement, net of offering costs	1,867
Proceeds from - Common Stock in Proteon Private Placement, net of offering costs	12,413
Proceeds from - Series 1 Convertible Preferred Stock in Proteon Private Placement, net of offering costs	25,319
Proceeds from Common Offering, net of offering costs	73,570
Proceeds from Preferred Offering, net of offering costs	66,284
Proceeds from Underwriters Overallotment Option	11,087
Repayments under short-term debt	(1,669)
Proceeds from the exercise of stock options	530
Proceeds from private placements		500
Net cash provided by financing activities	189,401	500
Net increase/(decrease) in cash and cash equivalents and restricted cash	168,829	(4,986)
Cash and cash equivalents and restricted cash - beginning of year	564	5,550
Cash and cash equivalents and restricted cash - end of year	169,393	564
Reconciliation of cash and cash equivalents and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	168,598	564
Restricted cash	50
Restricted cash, long-term	745
Cash and cash equivalents and restricted cash	169,393	564
Cash paid for:
Interest	34
Income Taxes
Non-cash investing and financing activities:
Deferred offering costs recorded in accrued expenses		122
Deferred offering costs recognized that were previously recorded in accrued expenses	122
Purchase of insurance agreement with notes payable	1,669
Common stock issued in connection with the reverse merger with ArTara Therapeutics, Inc.	$ 34,533